Test Price
2,800 AEDโ Home Collection Available
SCN2A Gene (Early Infantile Epileptic Encephalopathy Type 11) Genetic Test in UAE | 2800 AED | DHA-MOHAP Guidelines
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain, VIP Mobile Phlebotomy (8 AMโ11 PM).
- Clinical Guidance: Complimentary telephonic post-test clinical guidance by DHA-licensed genetics professional.
- Insurance: Direct Billing Verification โ WhatsApp +971 54 548 8731.
- Compliance: Fully adheres to UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Test Overview & Methodology
The SCN2A gene test employs Next Generation Sequencing to detect pathogenic variants associated with Early Infantile Epileptic Encephalopathy Type 11 (EIEE11), enabling precise diagnosis and tailored management.
This assay covers all coding exons and splice junctions, with confirmatory Sanger sequencing for identified variants, achieving >99.9% analytical sensitivity and specificity.
| Feature | Our Test (SCN2A NGS) | Closest Alternative (Sequential Single-Gene Sanger) |
|---|---|---|
| Precision | 99.9% sensitivity, full gene coverage | ~95%, limited to known hot-spots |
| Method | NGS (Next Generation Sequencing) with Sanger validation | Sanger sequencing of selected exons |
| Speed | 3โ4 weeks (comprehensive report) | 4โ6 weeks (often sequential) |
Physician Insight & Safety Protocols
โAs a Consultant Medical Genetics, I emphasize that a positive SCN2A result must be correlated with electroclinical findings; not all variants are pathogenic, and non-neurological phenotypes exist. Our team ensures thorough pre- and post-test counseling to navigate this complexity.โ
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue prescribed anti-epileptic medication without consulting your treating physician; abrupt cessation may trigger life-threatening seizures.
Exclusion Criteria & ER Red Flags
- Exclusion: Inability to provide informed consent (or legal guardian consent for minors).
- Exclusion: Acute intercurrent illness that precludes safe venipuncture.
- ER Red Flag: Prolonged seizure (>5 minutes) or repeated seizures without regaining consciousness โ seek emergency care immediately.
- ER Red Flag: New-onset focal neurological deficit or altered consciousness.
- ER Red Flag: Respiratory distress or cyanosis during feeding in neonatesโurgent evaluation needed.
Patient FAQ & Clinical Guidance
1. What is the SCN2A genetic test used for?
Answer: This test identifies mutations in the SCN2A gene that cause Early Infantile Epileptic Encephalopathy Type 11, enabling precise diagnosis, tailored anti-epileptic therapy, and family counseling. It is recommended for infants and children with early-onset seizures unresponsive to standard treatments. Testing can also clarify prognosis and recurrence risk for future pregnancies.
2. How do I prepare for the test and what sample is required?
Answer: A genetic counselling session and a detailed clinical history, including a family pedigree, are mandatory before sample collection. The sample can be blood (2-3 mL in EDTA tube), extracted DNA, or a few drops on an FTA card. Fasting is not required. Our home collection team will handle the cold-chain transport.
3. When will I receive my results and how are they interpreted?
Answer: Results are available within 3 to 4 weeks and include a detailed report classifying variants as pathogenic, likely pathogenic, or uncertain significance. Our DHA-licensed genetics professional will explain the findings, discuss implications for treatment, and advise on the need for parental testing. Any actionable result is communicated immediately via secure WhatsApp.
UAE Regulatory & Data Privacy Adherence
Data Privacy: This test is conducted in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is handled with strict confidentiality and secure storage.
Clinical Safety: Patient consent and medical liability are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Our facility is licensed by the Dubai Health Authority (DHA License No: 1143) and operates under ISO 9001:2015 certified processes.
Clinical & Logistical Metadata
| Test Name | SCN2A Gene (Early Infantile Epileptic Encephalopathy Type 11) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3โ4 Weeks (Comprehensive Report) |
| Sample Type / Matrix | Blood (2-3 mL EDTA), Extracted DNA, or FTA Card |
| Methodology Used | Next Generation Sequencing (NGS) with Sanger Validation |
| ICD-10-CM Code | G40.4 (Other generalized epilepsy and epileptic syndromes) |
| LOINC Code | 83190-8 (SCN2A gene mutation analysis) |
| DHA Facility License & Laboratory Address | DHA License No: 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians